Video
Graves' Disease: Old, Effective and New Treatments
Published: June 20, 2022
View Video chevron_rightFeatured Videos |view more
Graves' Disease: Old, Effective and New Treatments
This one-hour webinar features a comprehensive case-based discussion covering Graves’ Disease. The panel features a multidisciplinary team of experts from endocrine surgery, endocrinology, ophthalmology, and nuclear medicine. Learn about ...
Penn Surgeons Perform World’s First En Bloc Resection of Rare Chordoma Tumor
See how Penn Medicine surgeons removed a rare cervical chordoma en-bloc, using Trans Oral Robotic Surgery (TORS).
3D Modeling for Reconstructive Surgery | Virtual Surgical Planning (VSP) at Penn Medicine
Learn how 3D mapping and printing relate to reconstructive surgery at Penn Medicine, where Virtual Surgical Planning (VSP) technology is pivotal to the pre-surgical process.
TORS for Head & Neck Cancer Care: Innovative, Minimally-Invasive Surgery Technique Invented at Penn
TransOral Robotic Surgery (TORS) is a minimally-invasive, robot-assisted surgical technique to remove tumors of the mouth and throat that are difficult to reach through traditional surgery.
Penn Otorhinolaryngology: Innovative Expert Care for Complex Cases
At Penn Otorhinolaryngology – Head and Neck Surgery, we pride ourselves on being able to provide complex care for the most challenging and rare cases.
Overview of the Diagnosis and Early Management of Thyroid Cancer: Early signs of aggressive disease
Caroline Kim, MD, examines the warnings signs for aggressive and recurrent disease in patients lacking structurally identifiable disease after initial therapy.
The Management of the Medullary Thyroid Cancer Patient
Caroline S. Kim, MD, reviews the pathology and management of medullary thyroid cancer.
Surgery for Recurrent Thyroid Cancer: Considerations and Limitations
Surgeon Ara A. Chalian, MD, FACS, reviews the procedures and indications for surgery in the patient with recurrent thyroid cancer.
Approved: Sorafenib and Lenvatinib for the Treatment of Progressive, RAI-Refractory DTC
Marcia Brose, MD, discusses the treatment of radioiodine-refractory differentiated thyroid cancer with the kinase inhibitors sorafenib and lenvatinib.
Penn Medicine News